Inventor · disambiguated record
Tahmineh Safaie
Also filed as: SAFAIE TAHMINEH
8 granted patents·9 pending applications·4 citations·filing 2020–2025
80Inventor score
Files withNAMMI THERAPEUTICS INC17
Top patents by PatentIndex Score
17 records- 0192US11896646B2Formulated and/or co-formulated liposome compositions containing toll-like receptor (“TLR”) agonist prodrugs useful in the treatment of cancer and methods thereofNAMMI THERAPEUTICS INC·Filed 2022·Granted Feb 13, 2024·1 cites·16 claims
- 0287US11679141B2Formulated and/or co-formulated liposome compositions containing toll-like receptor (“TLR”) agonist prodrugs useful in the treatment of cancer and methods thereofNAMMI THERAPEUTICS INC·Filed 2021·Granted Jun 20, 2023·1 cites·9 claims
- 0386US11744874B2Formulated and/or co-formulated liposome compositions containing toll-like receptor (“TLR”) agonist prodrugs useful in the treatment of cancer and methods thereofNAMMI THERAPEUTICS INC·Filed 2020·Granted Sep 5, 2023·1 cites·9 claims
- 0485US12311010B2Formulated and/or co-formulated liposome compositions containing toll-like receptor(“TLR”) agonist prodrugs useful in the treatment of cancer and methods thereofNAMMI THERAPEUTICS INC·Filed 2023·Granted May 27, 2025·0 cites·14 claims
- 0585US11801304B2Formulated and/or co-formulated liposome compositions containing TFGB antagonist prodrugs useful in the treatment of cancer and methods thereofNAMMI THERAPEUTICS INC·Filed 2021·Granted Oct 31, 2023·1 cites·14 claims
- 0685US2024123028A1Formulated and/or Co-Formulated Liposome Compositions Containing Toll-Like Receptor ("TLR") Agonist Prodrugs Useful In The Treatment of Cancer and Methods Thereof CNAMMI THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 0782US2023277621A1Formulated and/or co-formulated liposome compositions containing toll-like receptor ("TLR") agonist prodrugs useful in the treatment of cancer and methods thereofNAMMI THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 0879US12059470B2Formulated and/or co-formulated liposome compositions containing PD-1 antagonist prodrugs useful in the treatment of cancer and methods thereofNAMMI THERAPEUTICS INC·Filed 2023·Granted Aug 13, 2024·0 cites·18 claims
- 0978US2025032620A1Formulated and/or Co-Formulated Nanocarrier Compositions Containing TFGß Antagonist Prodrugs Useful in the Treatment of Cancer and Methods ThereofNAMMI THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1076US2024366772A1Formulated and/or Co-Formulated Liposome Compositions Containing PD-1 Antagonist Prodrugs Useful in the Treatment of Cancer and Methods ThereofNAMMI THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1175US2025313531A1Formulated and/or Co-Formulated Liposome Compositions Containing IDO Antagonist Prodrugs Useful in the Treatment of Cancer and Methods ThereofNAMMI THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1275US2025177484A1Formulated and/or Co-Formulated Liposome Compositions Containing Toll-Like Receptor (TLR) Agonist Prodrugs Useful in the Treatment of Cancer and Methods ThereofNAMMI THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 1375US2024050575A1Formulated and/or co-formulated liposome compositions containg TGFb antagonist prodrugs useful in the treatment of cancer and methods thereofNAMMI THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1473US11833209B2Formulated and/or co-formulated liposome compositions containing PD-1 antagonist prodrugs useful in the treatment of cancer and methods thereofNAMMI THERAPEUTICS INC·Filed 2021·Granted Dec 5, 2023·0 cites·15 claims
- 1568US12286403B2Formulated and/or co-formulated liposome compositions containing IDO antagonist prodrugs useful in the treatment of cancer and methods thereofNAMMI THERAPEUTICS INC·Filed 2020·Granted Apr 29, 2025·0 cites·19 claims
- 1658US2023226031A1Formulated and/or Co-Formulated Liposome Compositions Containing Immunogenic Cell Death (ICD) Inducing Prodrugs Useful In The Treatment of Cancer and Methods ThereofNAMMI THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1757US2022401451A1Formulated and/or co-formulated compositions containing A2aR antagonist prodrugs useful in the treatment of cancer and methods thereofNAMMI THERAPEUTICS INC·Filed 2022·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Tahmineh Safaie files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →